Andersons pediatric cardiology 1945

182.AgnolettiG,FerraroG,BordeseR,etal.Fontan
circulationcausesearly,severeliverdamage.
Shouldweofferpatientsatailoredstrategy?Int
JCardiol.2016;209:60–65.
183.HeyneK,ShinYS,SchwingerE.Double
heterozygosity(transferase-/epimerase-defect)
andgalactosemiacataract.Monatsschr
Kinderheilkd.1988;136(12):828–830.
184.WernovskyG,LihnSL,OlenMM.Creatinga
lesion-specific“roadmap”forambulatorycare
followingsurgeryforcomplexcongenital
cardiacdisease.CardiolYoung.2017;27(4):648–
662.
185.GewilligM,GoldbergDJ.Failureofthefontan
circulation.HeartFailClin.2014;10(1):105–
116.
186.RychikJ,GoldbergD,RandE,etal.End-organ
consequencesoftheFontanoperation:liver
fibrosis,protein-losingenteropathyandplastic
bronchitis.CardiolYoung.2013;23(6):831–840.
187.DoriY.Novellymphaticimagingtechniques.
TechVascIntervRadiol.2016;19(4):255–261.
188.ItkinM,PiccoliDA,NadolskiG,etal.Proteinlosingenteropathyinpatientswithcongenital
heartdisease.JAmCollCardiol.
2017;69(24):2929–2937.
189.ItkinMG,McCormackFX,DoriY.Diagnosis


andtreatmentoflymphaticplasticbronchitisin
adultsusingadvancedlymphaticimagingand
percutaneousembolization.AnnAmThoracSoc.

2016;13(10):1689–1696.
190.LudwigJ,LinhartP,BaggenstossAH.Hepatic
lymphdrainageincirrhosisandcongestiveheart
failure.Apostmortemlymphangiographicstudy.
ArchPathol.1968;86(5):551–562.
191.AvitabileCM,GoldbergDJ,DoddsK,etal.A
multifacetedapproachtothemanagementof
plasticbronchitisaftercavopulmonary
palliation.AnnThoracSurg.2014;98(2):634–
640.
192.RaczJ,ManeG,FordM,etal.
Immunophenotypingandproteinprofilingof
Fontan-associatedplasticbronchitisairway
casts.AnnAmThoracSoc.2013;10(2):98–107.
193.SchumacherKR,StringerKA,DonohueJE,et
al.Fontan-associatedprotein-losingenteropathy
andplasticbronchitis.JPediatr.
2015;166(4):970–977.
194.DoriY,ItkinM.Etiologyandnewtreatment
optionsforpatientswithplasticbronchitis.J
ThoracCardiovascSurg.2016;152(2):e49–e50.
195.BrooksK,CaruthersRL,SchumacherKR,
StringerKA.Pharmacotherapychallengesof
Fontan-associatedplasticbronchitis:arare


pediatricdisease.Pharmacotherapy.
2013;33(9):922–934.
196.LubckeNL,NussbaumVM,SchrothM.Useof
aerosolizedtissueplasminogenactivatorinthe

treatmentofplasticbronchitis.Ann
Pharmacother.2013;47(3):e13.
197.DoriY,KellerMS,RomeJJ,etal.Percutaneous
lymphaticembolizationofabnormalpulmonary
lymphaticflowastreatmentofplasticbronchitis
inpatientswithcongenitalheartdisease.
Circulation.2016;133(12):1160–1170.
198.RychikJ.Protein-losingenteropathyafterFontan
operation.CongenitHeartDis.2007;2:288–300.
199.JohnAS,JohnsonJA,KhanM,etal.Clinical
outcomesandimprovedsurvivalinpatientswith
protein-losingenteropathyaftertheFontan
operation.JAmCollCardiol.2014;64(1):54–62.
200.MertensL,HaglerD,SauerU,SomervilleJ,
GewilligM.Protein-losingenteropathyafterthe
Fontanoperation:aninternationalmulticenter
study.PLEstudygroup.JThoracCardiovasc
Surg.1998;115(5):1063–1073.
201.GoldbergDJ,DoddsK,AvitabileCM,etal.
Childrenwithprotein-losingenteropathyafter
theFontanoperationareatriskforabnormal
bonemineraldensity.PediatrCardiol.
2012;33(8):1264–1268.